Medication-info.com Search Menu

Paclitaxel (Abraxane): Uses, Side Effects and Dosage

Updated:
Facts
Status:
Prescription (Rx) Boxed warning
Strength:
100 mg/20 mL
Brand names:
Drug class:
Active ingredient:
Similar drugs:

Source: FDA drug labeling via NLM DailyMed · About this document

Patient information: uses, side effects, how to take - Paclitaxel

What is Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound)?

Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound) is a prescription medicine used to treat:

  • advanced breast cancer in people who have already received certain other medicines for their cancer.
  • advanced non-small cell lung cancer (NSCLC), in combination with carboplatin in people who cannot be treated with surgery or radiation.
  • advanced pancreatic cancer, when used in combination with gemcitabine as the first medicine for advanced pancreatic cancer.

It is not known if Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound) is safe and effective in children.

Do not receive Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound) if:

  • your white blood cell count is below 1,500 cells/ mm3.
  • you have had a severe allergic reaction to protein bound paclitaxel.

Before you receive Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound), tell your healthcare provider about all of your medical conditions, including if you:

  • have liver or kidney problems.
  • had a prior allergic reaction to a taxane.

  • are pregnant or plan to become pregnant. Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound) can harm your unborn baby.

Females who are able to become pregnant:

  • Your healthcare provider will check to see if you are pregnant before you start treatment with Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound).
  • You should not become pregnant during your treatment and for at least six months after your last dose of Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound).

  • You should use effective birth control (contraception) during your treatment and for at least six months after your last dose of Paclitaxel Protein-Bound Particles for Injectable Suspension

    (albumin-bound). Talk to your healthcare provider about birth control methods you can use during this time.

Males with a female sexual partner who can become pregnant:

  • Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound) can harm the unborn baby of your partner.
  • You should not father a child during your treatment and for at least three months after your last dose of Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound).
  • You should use effective birth control (contraception) during your treatment and for at least three months after your last dose of Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound).
  • are breastfeeding or plan to breastfeed. Do not breastfeed during your treatment and for two weeks after your last dose of Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound).

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Know the medicines you take. Keep a list to show your healthcare provider and pharmacist when you get a new medicine.

How will I receive Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound)?

  • Your healthcare provider will prescribe Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound) in an amount that is right for you.
  • Your healthcare provider may give you certain medicines to help prevent allergic reactions if you have had an allergic reaction to protein bound paclitaxel in the past.
  • Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound) will be given to you by intravenous (IV) infusion over 30 minutes into your vein.
  • Your healthcare provider should do blood tests regularly during treatment with Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound).
  • Your healthcare provider may stop your treatment, delay your treatment, or change your dose of Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound) if you have certain side effects.

What are the possible side effects of Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound)?

Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound) may cause serious side effects, including:

  • severe decreased blood cell counts. Protein bound paclitaxel can cause a severe decrease in neutrophils, a type of white blood cell which helps fight infections, and blood cells called platelets which help to clot blood. Your healthcare provider will check your blood cell count during your treatment with Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound).
  • severe nerve problems (neuropathy). Nerve problems are common with Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin bound) but can also sometimes be severe. Tell your healthcare provider if you have numbness, tingling, pain, or weakness in your hands or feet.
  • severe infection (sepsis). Infections can be severe and life-threatening in people who receive protein bound paclitaxel. Tell your healthcare provider right away if you have a fever (temperature greater than 100.4° F) or develop signs of infection.
  • lung or breathing problems. If you receive protein bound paclitaxel, lung or breathing problems may be severe and can lead to death. Tell your healthcare provider right away if you suddenly get a dry cough that will not go away or shortness of breath.
  • severe allergic reactions. Severe allergic reactions are medical emergencies that can happen in people who receive protein bound paclitaxel and can lead to death. You may have an increased risk of having an allergic reaction to Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound) if you are allergic to protein bound paclitaxel and other taxane medicines. Your healthcare provider will monitor you closely for allergic reactions during your infusion of Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound). Tell your healthcare provider right away if you get any of these signs of a serious allergic reaction: trouble breathing, sudden swelling of your face, lips, tongue, throat, or trouble swallowing, hives (raised bumps), rash, or redness all over your body.

The most common side effects of protein bound paclitaxel in people with breast cancer include:

  • hair loss
  • tiredness or weakness
  • changes in your liver function tests
  • nausea
  • infections
  • diarrhea
  • decreased white blood cell count
  • abnormal heartbeat
  • joint and muscle pain
  • low red blood cell count (anemia). Red blood cells carry oxygen to your body tissues. Tell your healthcare provider if you feel weak, tired, or short of breath.

The most common side effects of protein bound paclitaxel in people with non-small cell lung cancer include:

  • low red blood cell count (anemia)
  • decreased platelet cell count
  • tiredness/weakness
  • decreased white blood cell count
  • hair loss
  • nausea

The most common side effects of protein bound paclitaxel in people with pancreatic cancer include:

  • decreased white blood cell count
  • hair loss
  • infections
  • vomiting
  • rash
  • tiredness/weakness
  • nausea
  • swelling in the hands or feet
  • fever
  • decreased appetite
  • signs of dehydration including thirst, dry mouth, dark yellow urine, decreased urine, headache, or muscle cramps

Tell your healthcare provider if you have vomiting, diarrhea, or signs of dehydration that does not go away.

Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound) may cause fertility problems in males and females, which may affect your ability to have a child. Talk to your healthcare provider if this is a concern for you. These are not all of the possible side effects of Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound).

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound).

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your healthcare provider or pharmacist for information about Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound) that is written for health professionals.

What are the ingredients in Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound)?

Active ingredient: paclitaxel

Inactive ingredients: human albumin (containing sodium caprylate and sodium acetyltryptophanate), sodium chloride.

Manufactured By: Pharmachemie B.V., Haarlem, The Netherlands

Manufactured For: Teva Pharmaceuticals, Parsippany, NJ 07054

For more information, call Teva at 1-888-838-2872.

This Patient Information has been approved by the U.S. Food and Drug Administration. Iss. 11/2023

About this document

Source: FDA drug labeling via NLM DailyMed · Application number: NDA 216338 · View the label on DailyMed

Revision date stated in the text: November 2023

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Paclitaxel

Rx or OTC
Prescription (Rx)?
  • This drug is available only with a prescription from a licensed healthcare provider.
  • Rx
Boxed warning Yes – this drug has a boxed warning (also called a black box warning), the strongest warning of the FDA.
Drug class Microtubule Inhibitor
Active ingredient Paclitaxel 100 mg/20 mL
Dosage form Injection, powder, lyophilized, for suspension
Route Intravenous
Marketing status listed in the FDA NDC Directory
Company (applicant) TEVA PHARMS INC
FDA approval NDA 216338New Drug Application (NDA) Approved May 11, 2023
Reference listed drug This is the reference listed drug (RLD) that generics are compared with.
Therapeutic equivalence (TE) code ABCodes starting with A mean the FDA rates the drug therapeutically equivalent to its reference drug (Orange Book).
Generics Abraxane with the same TE code
Manufacturers 21 labelers list this drug on DailyMed
Packages (NDC)
Package
100 mg/20 mL – 20 ml in 1 vial, single-dose / 1 in 1 carton NDC 0480-3290-01

Source: FDA drug labeling via NLM DailyMed, data as of October 31, 2026. FDA data (DailyMed, Orange Book, Drug Shortages, enforcement reports). Not a substitute for the advice of a doctor or pharmacist.